133 related articles for article (PubMed ID: 34865347)
1. [Study on early predictive factors of an incomplete viral response with 48 week-entecavir therapy in HBeAg-positive chronic hepatitis B patients].
Zhou ZF; Ding Y; Zhang C; Fan YX; Dou XG
Zhonghua Gan Zang Bing Za Zhi; 2020 Dec; 28(12):1008-1012. PubMed ID: 34865347
[No Abstract] [Full Text] [Related]
2. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of efficacy and factors influencing sequential combination therapy with tenofovir alafenamide fumarate after treatment with entecavir in chronic hepatitis B patients with low-level viremia].
Liu LP; Wu XP; Cai TP; Wang L; Sun J; Liang JY; Ma SP; Gan X; Ruan NH; Ge SF
Zhonghua Gan Zang Bing Za Zhi; 2023 Feb; 31(2):118-125. PubMed ID: 37137825
[No Abstract] [Full Text] [Related]
4. Dynamic changes of cytokine profiles and virological markers during 48 weeks of entecavir treatment for HBeAg-positive chronic hepatitis B.
Li M; Gao Y; Yang L; Lin Y; Deng W; Jiang T; Bi X; Lu Y; Zhang L; Shen G; Liu R; Wu S; Chang M; Xu M; Hu L; Song R; Jiang Y; Yi W; Xie Y
Front Immunol; 2022; 13():1024333. PubMed ID: 36203581
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.
Choi HN; Song JE; Lee HC; Jo HH; Lee CH; Kim BS
Clin Mol Hepatol; 2015 Mar; 21(1):24-31. PubMed ID: 25834799
[TBL] [Abstract][Full Text] [Related]
6. Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients.
Luo H; Zhang XX; Cao LH; Tan N; Kang Q; Xi HL; Yu M; Xu XY
World J Gastroenterol; 2019 Feb; 25(6):719-728. PubMed ID: 30783375
[TBL] [Abstract][Full Text] [Related]
7. Partial virological response to entecavir treatment in nucleos(t)ide-naïve patients with HBeAg-positive chronic hepatitis B is not caused by reduced sensitivity.
Li X; Li F; Zhang Y; Kang Y; Yu J; Yang F; Liu H; Qin Y; Huang Y; Mao R; Zhang J
Biochem Biophys Res Commun; 2015 Sep; 464(4):1185-1191. PubMed ID: 26212437
[TBL] [Abstract][Full Text] [Related]
8. On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B.
Huang YJ; Chang CS; Peng YC; Yeh HZ; Yang SS
PLoS One; 2017; 12(3):e0174046. PubMed ID: 28350873
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.
Qiu YW; Huang LH; Yang WL; Wang Z; Zhang B; Li YG; Su TT; Zhou HY; Xu W; Wang XD; Dai YP; Gan JH
Int J Infect Dis; 2016 Feb; 43():43-48. PubMed ID: 26523639
[TBL] [Abstract][Full Text] [Related]
10. Prolonged entecavir therapy is not effective for HBeAg seroconversion in treatment-naive chronic hepatitis B patients with a partial virological response.
Lee HW; Kwon JC; Oh IS; Chang HY; Cha YJ; Choi IS; Kim HJ
Antimicrob Agents Chemother; 2015 Sep; 59(9):5348-56. PubMed ID: 26100697
[TBL] [Abstract][Full Text] [Related]
11. Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy.
Ko SY; Choe WH; Kwon SY; Kim JH; Seo JW; Kim KH; Lee CH
Scand J Gastroenterol; 2012 Nov; 47(11):1362-7. PubMed ID: 22934534
[TBL] [Abstract][Full Text] [Related]
12. On-treatment HBV DNA level could predict HBeAg seroclearance in patients with HBeAg-positive chronic hepatitis B with entecavir therapy.
Huang YJ; Chang CS; Peng YC; Yeh HZ; Yang SS
J Chin Med Assoc; 2017 Jun; 80(6):341-346. PubMed ID: 28314596
[TBL] [Abstract][Full Text] [Related]
13. Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels.
Shin JW; Jung SW; Park BR; Kim CJ; Eum JB; Kim BG; Jeong ID; Bang SJ; Lee SH; Kim SR; Park NH
J Viral Hepat; 2012 Oct; 19(10):724-31. PubMed ID: 22967104
[TBL] [Abstract][Full Text] [Related]
14. [Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].
Shi H; Li XY; Zhu JY; Lin CS; Zhang Y
Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):721-725. PubMed ID: 29108198
[No Abstract] [Full Text] [Related]
15. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response.
Zoutendijk R; Reijnders JG; Brown A; Zoulim F; Mutimer D; Deterding K; Petersen J; Hofmann WP; Buti M; Santantonio T; van Bömmel F; Pradat P; Oo Y; Luetgehetmann M; Berg T; Hansen BE; Wedemeyer H; Janssen HL;
Hepatology; 2011 Aug; 54(2):443-51. PubMed ID: 21563196
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
17. HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients.
Peng CY; Hsieh TC; Hsieh TY; Tseng KC; Lin CL; Su TH; Tseng TC; Lin HH; Wang CC; Kao JH
J Formos Med Assoc; 2015 Apr; 114(4):308-13. PubMed ID: 24315616
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of addition of Tenofovir Disoproxil Fumarate to Peg-IFNα-2b is superior to the addition of Entecavir in HBeAg positive CHB patients with a poor response after 12 weeks of Peg-IFNα-2b treatment alone.
Lin S; Fu Y; Wu W; Chen T; Chen N; Xun Z; Liu C; Ou Q; Zeng Y; Huang H
Int J Med Sci; 2020; 17(10):1458-1463. PubMed ID: 32624702
[No Abstract] [Full Text] [Related]
19. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J
Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670
[TBL] [Abstract][Full Text] [Related]
20. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
Gish RG; Chang TT; Lai CL; de Man RA; Gadano A; Llamoso C; Tang H
Antivir Ther; 2013; 18(5):691-8. PubMed ID: 23510982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
